Product Program year 2023 Source: CMS Open Payments

Motegrity

Drug Internal Medicine

NDC 54092-546-01

Open in the dashboard

General payments

$853,429

20,345 payments

Research payments

$40,500

9 payments

Through program year 2023, $853,429 in general payments and $40,500 in research payments were reported against Motegrity (Internal Medicine).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

6 rows
Year Kind Amount Payments
2023 General $2,438 4
2022 General $35,240 1,327
2021 General $403,396 11,575
2021 Research $40,500 9
2020 General $390,788 7,404
2019 General $21,567 35

Breakdown

Who paid General payments · program years 2019–2023
  1. Takeda Pharmaceuticals U.S.A., Inc. $841,705 20,333 payments
  2. Shire North American Group Inc $11,724 12 payments
Top recipients General payments · program year 2023
  1. Peter Kowey Cardiovascular Disease · Wynnewood, PA $1,219 50% · 2 payments
  2. Bahij Kreidieh Clinical Cardiac Electrophysiology · Evergreen Park, IL $1,219 50% · 2 payments

Each share is of general payments naming this product in 2023.

Specialties paid General payments · program year 2023
  1. Clinical Cardiac Electrophysiology Internal Medicine $1,219 50% · 1 practitioner
  2. Cardiovascular Disease Internal Medicine $1,219 50% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2023
  1. Pennsylvania $2,438 100% · 2 recipients

Each share is of general payments naming this product in 2023 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

56,364

Prescriptions dispensed, refills included

Drug cost

$40,654,800

Paid at the pharmacy, in all

Prescribers

2,568

With 11 or more claims of it

Medicare Part D drugs matched to MOTEGRITY, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Motegrity Prucalopride Succinate Same name 2,568 56,364 $40,654,800

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Irene Sonu Gastroenterology CA 260 $167,140 None on record
Mayra Sanchez De La Cruz Gastroenterology CT 239 $152,948 None on record
Michael Cline Gastroenterology OH 233 $145,304 None on record
Sarah Knauf Nurse Practitioner CT 213 $191,757 None on record
Dorna Yaghoobzadeh Physician Assistant CA 174 $117,838 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
20,345 general · 9 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record